 |
|
|
| |
Cost Effectiveness of Hepatitis C Treatment
|
| |
| |
Reported by Jules Levin
DDW 2015 - Digestive Disease Week 2015, May 16-19, 2015, Washington D.C.
Nancy Reau, MD
Associate Professor of Medicine
University of Chicago
Reference: Rein, D. B., et al. (2011). "Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States." Dig Liver Dis 43(1): 66-72
(Davis et al Gastroenterology 2010) Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease Progression......http://www.natap.org/2010/HCV/031110_02.htm
Van der Meer JAMA 2012 - CLINICAL EFFICACY OF HIGHLY EFFECTIVE INTERFERON-FREE THERAPY IN PATIENTS WITH CHRONIC HCV INFECTION AND COMPENSATED ADVANCED HEPATIC FIBROSIS - Life Expectancy in Patients With Chronic HCV Infection and Cirrhosis Compared With a General Population.........http://www.natap.org/2014/AASLD/AASLD_89.htm
The quality-adjusted life year or quality-adjusted life-year (QALY) is a measure of disease burden, including both the quality and the quantity of life lived. It is used in assessing the value for money of a medical intervention.
Pricing of Drugs and Formulary Placement: Making Sense of Hepatitis C Treatment Camilla S. Graham, MD, MPH......http://www.natap.org/2015/HCV/040815_04.htm
Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease - (03/16/15) Leidner Hepatology 2025
The Cost-effectiveness, Health Benefits, and Financial Costs of New Antiviral Treatments for Hepatitis C Virus and Editorial - (03/16/15) Rein CID 2025
Cost-Effectiveness of Novel Regimens for the Treatment of Hepatitis C Virus - (03/18/15) .....17 March 2015 Ann Intern Med....Mehdi Najafzadeh, PhD
Cost-Effectiveness and Budget Impact of Hepatitis C Virus Treatment With Sofosbuvir and Ledipasvir in the United States - (03/18/15).....17 March 2015 Ann Intern Med......Jagpreet Chhatwal, PhD
EASL: Improvement in Liver Function and Non-Invasive Estimates of Liver Fibrosis 48 Weeks after Treatment With Ombitasvir/Paritaprevir/r, Dasabuvir, and Ribavirin in HCV Genotype 1 Patients With Cirrhosis - (04/24/15) post-SVR markers of HCV disease improved including all- non-ivasive estimates of liver fibrosis - FibroTest, APRI, FIB-4, FORNS Index
EASL: HEALTHCARE ECONOMICS / SVR Improves Health, Mortality / Early HCV Therapy Prefer - (05/14/15)
EASL: Effect of Long-Term Viral Suppression With Sofosbuvir + Ribavirin on Hepatic Venous Pressure Gradient in HCV-Infected Patients With Cirrhosis and Portal Hypertension - (04/29/15)
EASL: Time Course of Hepatic Improvement using the HepQuant® (HQ)-SHUNT Function Test during and after Treatment with Ledipasvir/Sofosbuvir in Liver Transplant Recipients with Allograft Fibrosis or Cirrhosis and Patients with Decompensated Cirrhosis who have not undergone Transplantation - (04/29/15)
HCV Treatment Cost-Effective Unitedhealthcare's OPTUMRx PBM says.....http://www.natap.org/2014/HCV/062514_07.htm
NATAP: SVR Improves Health / Cost Outcomes - (05/15/15)
Cost-Effectiveness and Budget Impact of Hepatitis C Virus Treatment With Sofosbuvir and Ledipasvir in the United States - (03/18/15).....17 March 2015 Ann Intern Med......Jagpreet Chhatwal, PhD
McCombs Study: EASL: CAN HEPATITIS C TREATMENT BE SAFELY DELAYED?: EVIDENCE FROM THE VETERANS ADMINISTRATION HEALTHCARE SYSTEM - (04/28/15)
|
| |
|
|
|
|
|
